A DETAILED REVIEW ON HEPATITIS B VIRUS (HBV)

Reshmi T Nair Ph.D. Scholar, Jaipur Engineering College and Research Centre University, Jaipur, Rajasthan, India. reshmitnair19@gmail.com
Bharti Malhotra* Senior Professor, Department of Microbiology, SMS Medical College & Hospital, Jawahar Lal Nehru Marg, Jaipur 302004, India. drbhartimalhotra@gmail.com
Sonali Pandey HOD Department of Botany, Jaipur Engineering College and Research Centre University, Jaipur, Rajasthan, India, drsonali17@gmail.com

Abstract

Hepatitis B virus infection has become a major public health problem worldwide, approximately 30% of the world's population show serological evidence of current or past infection. Inflammation of the liver, vomiting, jaundice, and mortality are all symptoms of the acute sickness. Chronic hepatitis impact to global morbidity and mortality is typically underestimated because it is a "silent" disease. Both the incidence of new infections and the risk of chronic liver disease must be reduced as part of hepatitis B and C prevention and control. The prevention and detection of HBV and HCV infections should be done by comprehensive public health prevention program. HBV infection can be prevented by taking universal precautions in health-care settings, such as avoiding needle-stick injuries and instituting post-exposure prophylaxis. The present study focuses on the effects of vaccination and also a detailed review has been conducted over the HBV genotype/genetic characterization and HBV mutation/genetic variability.

Keywords:

:

: Hepatitis B virus, HBV genotype, Vaccination, HBV Awarness, Serological markers

Full Text:

PDF


References


References: 1. Abu-Amara, Mahmoud, Orlando Cerocchi, Gurtej Malhi, Suraj Sharma, ColinaYim, Hemant Shah, David K. Wong, Harry LA Janssen, and Jordan J. Feld. "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection." Gut 65, no. 8 (2016): 1347-1358. 2. Aggarwal, R., Babu, J. J., Hemalatha, R., Reddy, A. V., Sharma, D., & Kumar, T. (2014). Effect of inclusion of hepatitis B vaccine in childhood immunization program in India: a retrospective cohort study. Indian pediatrics, 51(11), 875-879. 3. Alfaiate, Dulce, Julie Lucifora, Natali Abeywickrama-Samarakoon, Maud Michelet, Barbara Testoni, Jean-Claude Cortay, Camille Sureau, Fabien Zoulim, Paul Dény, and David Durantel. "HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes." Antiviral research 136 (2016): 19-31. 4. Andernach, I. E., Hunewald, O. E., & Muller, C. P. (2013). Bayesian inference of the evolution of HBV/E. PLoS One, 8(11), e81690. 5. Araujo, N. M., Waizbort, R., & Kay, A. (2011). Hepatitis B virus infection from an evolutionary point of view: how viral, host, and environmental factors shape genotypes and subgenotypes. Infection, Genetics and Evolution, 11(6), 1199-1207. 6. Bhattacharya, H., Bhattacharya, D., Ghosal, S. R., Roy, S., &Sugunan, A. P. (2015). Status of hepatitis B infection-a decade after hepatitis B vaccination of susceptible Nicobarese, an indigenous tribe of Andaman & Nicobar (A&N) islands with high hepatitis B endemicity. The Indian journal of medical research, 141(5), 653. 7. Bismuth, H., Majno, P. E., & Adam, R. (1999). Liver transplantation for hepatocellular carcinoma. In Seminars in liver disease (Vol. 19, No. 03, pp. 311-322). © 1999 by Thieme Medical Publishers, Inc.. 8. Bouckaert, R., Alvarado-Mora, M. V., &Pinho, J. R. (2013). Evolutionary rates and HBV: issues of rate estimation with Bayesian molecular methods. AntivirTher, 18(3 Pt B), 497-503. 9. Brakenhoff, S. M., de Man, R. A., de Knegt, R. J., Janssen, H. L., &Sonneveld, M. J. (2021). HBV cure—the quest for biomarkers to predict off‐treatment sustained response. Authors' reply. 10. Butler, E. K., Gersch, J., McNamara, A., Luk, K. C., Holzmayer, V., de Medina, M., ... &Cloherty, G. A. (2018). Hepatitis B virus serum DNA and RNA levels in nucleos (t) ide analog‐treated or untreated patients during chronic and acute infection. Hepatology, 68(6), 2106-2117. 11. Carman, W. F., Karayiannis, P., Waters, J., Thomas, H. C., Zanetti, A. R., Manzillo, G., & Zuckerman, A. T. (1990). Vaccine-induced escape mutant of hepatitis B virus. The lancet, 336(8711), 325-329. 12. Cho, E. J., Kim, S. E., Suk, K. T., An, J., Jeong, S. W., Chung, W. J., & Kim, Y. J. (2017). Current status and strategies for hepatitis B control in Korea. Clinical and molecular hepatology, 23(3), 205. 13. Chu, C. M., &Liaw, Y. F. (2006, May). Hepatitis B virus-related cirrhosis: natural history and treatment. In Seminars in liver disease (Vol. 26, No. 02, pp. 142-152). Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. 14. Cooreman, M. P., Leroux-Roels, G., &Paulij, W. P. (2001). Vaccine-and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. Journal of biomedical science, 8(3), 237-247. 15. Datta, S., Chatterjee, S., Veer, V., & Chakravarty, R. (2012). Molecular biology of the hepatitis B virus for clinicians. Journal of clinical and experimental hepatology, 2(4), 353-365. 16. Din, A., Li, Y., & Shah, M. A. (2021). The complex dynamics of Hepatitis B infected individuals with optimal control. Journal of Systems Science and Complexity, 1-23. 17. Duong, C. M., Olszyna, D. P., &McLaws, M. L. (2015). Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC public health, 15(1), 1-7. 18. European Association For The Study Of The Liver. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology, 67(2), 370-398. 19. FitzSimons, D., Francois, G., De Carli, G., Shouval, D., Prüss-Üstün, A., Puro, V., ... & Van Damme, P. (2008). Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occupational and Environmental Medicine, 65(7), 446-451. 20. Gao, Yuhua, Yutang Li, Qinghua Meng, Zhanqing Zhang, Ping Zhao, Qinghua Shang, Yue Li et al. "Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos (t) ide analogue treatment?." Journal of clinical microbiology 55, no. 10 (2017): 2972-2982. 21. Ghosh, S., Banerjee, P., Deny, P., Mondal, R. K., Nandi, M., Roychoudhury, A., ... & Datta, S. (2013). New HBV subgenotype D 9, a novel D/C recombinant, identified in patients with chronic HB e A g‐negative infection in E astern I ndia. Journal of Viral Hepatitis, 20(3), 209-218. 22. Günal, Ö., Barut, Ş., Etikan, İ., Duygu, F., Tuncel, U., &Sünbül, M. (2014). Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection. Turk J Gastroenterol, 25(1), 142-6. 23. HönerzuSiederdissen, Christoph, Aric Josun Hui, Wattana Sukeepaisarnjaroen, PisitTangkijvanich, Wei Wen Su, Gerardo Enrique Guillén Nieto, Paul Gineste et al. "Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients." The Journal of infectious diseases 218, no. 9 (2018): 1480-1484. 24. Ibrahim, N., & Idris, A. (2014). Hepatitis B awareness among medical students and their vaccination status at Syrian Private University. Hepatitis research and treatment, 2014. 25. Iida-Ueno, A., Enomoto, M., Tamori, A., & Kawada, N. (2017). Hepatitis B virus infection and alcohol consumption. World journal of gastroenterology, 23(15), 2651. 26. Inoue, Jun, Masashi Ninomiya, TeruyukiUmetsu, Takuya Nakamura, Takayuki Kogure, Eiji Kakazu, Tomoaki Iwata et al. "Small interfering RNA screening for the small GTPase Rab proteins identifies Rab5B as a major regulator of hepatitis B virus production." Journal of virology 93, no. 15 (2019): e00621-19. 27. Kay, A., &Zoulim, F. (2007). Hepatitis B virus genetic variability and evolution. Virus research, 127(2), 164-176. 28. Khalili, M., Shuhart, M. C., Lombardero, M., Feld, J. J., Kleiner, D. E., Chung, R. T, Lok, A. S. (2018). Relationship between metabolic syndrome, alanine aminotransferase levels, and liver disease severity in a multiethnic north American cohort with chronic hepatitis B. Diabetes care, 41(6), 1251-1259. 29. Khan, J., Shil, A., & Mohanty, S. K. (2019). Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants. BMC Public Health, 19(1), 1-14. 30. Kidd-Ljunggren, K., Miyakawa, Y., & Kidd, A. H. (2002). Genetic variability in hepatitis B viruses. Journal of General Virology, 83(6), 1267-1280. 31. Kramvis, A. (2014). Genotypes and genetic variability of hepatitis B virus. Intervirology, 57(3-4), 141-150. 32. Kramvis, A. (2014). Genotypes and genetic variability of hepatitis B virus. Intervirology, 57(3-4), 141-150. Komatsu H, Inui A, and Fujisawa T, “The role of body fluidsin the horizontal transmission of hepatitis B virus via household/close contact,” EMJ, vol. 1, no. 1, pp. 68–75, 2016. 33. Lahariya, C., Subramanya, B. P., &Sosler, S. (2013). An assessment of hepatitis B vaccine introduction in India: Lessons for roll out and scale up of new vaccines in immunization programs. Indian journal of public health, 57(1), 8. 34. Lahariya, C., Subramanya, B. P., &Sosler, S. (2013). An assessment of hepatitis B vaccine introduction in India: Lessons for roll out and scale up of new vaccines in immunization programs. Indian journal of public health, 57(1), 8. 35. Lazarevic, I., Banko, A., Miljanovic, D., &Cupic, M. (2019). Immune-escape hepatitis B virus mutations associated with viral reactivation upon immunosuppression. Viruses, 11(9), 778. 36. Lin, C. L., & Kao, J. H. (2011). The clinical implications of hepatitis B virus genotype: Recent advances. Journal of gastroenterology and hepatology, 26, 123-130. 37. Lin, C. W., Lin, C. C., Mo, L. R., Chang, C. Y., Perng, D. S., Hsu, C. C., ... & Yang, S. S. (2013). Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. Journal of hepatology, 58(4), 730-735. 38. Liu, C. J., & Kao, J. H. (2013, May). Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. In Seminars in liver disease (Vol. 33, No. 02, pp. 097-102). Thieme Medical Publishers. 39. Locarnini, S., & Mason, W. S. (2006). Cellular and virological mechanisms of HBV drug resistance. Journal of hepatology, 44(2), 422-431. 40. Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M. Protzer, U. (2011). Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Journal of hepatology, 55(5), 996-1003. 41. Mak, L. Y., Seto, W. K., Fung, J., & Yuen, M. F. (2019). New biomarkers of chronic hepatitis B. Gut and liver, 13(6), 589. 42. Mogul, D. B., Brereton, N., Carson, K. A., Pittarelli, M., Daniel, H., Torbenson, M., & Schwarz, K. B. (2018). Development of a Dietary Methyl Donor Food Frequency Questionnaire to Assess Folate and Vitamin B12 Status in Children with Chronic Hepatitis B Virus Infection. The Journal of pediatrics, 203, 41-46. 43. Moorman AC, de Perio MA, Goldschmidt R, Chu C, Kuhar D, Henderson DK, Naggie S, Kamili S, Spradling PR, Gordon SC, Russi MB. Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus-CDC Guidance, United States, 2020. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. 2020 Jul 24;69(6):1-8. 44. Moura, I. F., Lopes, E. P., Alvarado-Mora, M. V., Pinho, J. R., &Carrilho, F. J. (2013). Phylogenetic analysis and subgenotypic distribution of the hepatitis B virus in Recife, Brazil. Infection, Genetics and Evolution, 14, 195-199. 45. Nelson, N. P., Easterbrook, P. J., & McMahon, B. J. (2016). Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clinics in liver disease, 20(4), 607-628. 46. Ntziora, F., D. Paraskevis, C. Haida, E. Magiorkinis, E. Manesis, G. Papatheodoridis, S. Manolakopoulos et al. "Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology." Journal of clinical microbiology 47, no. 8 (2009): 2544-2550. 47. Pan, Calvin Q., Zhongping Duan, Erhei Dai, Shuqin Zhang, Guorong Han, Yuming Wang, Huaihong Zhang et al. "Tenofovir to prevent hepatitis B transmission in mothers with high viral load." New England journal of medicine 374, no. 24 (2016): 2324-2334. 48. Paraskevis, D., Magiorkinis, G., Magiorkinis, E., Ho, S. Y., Belshaw, R., Allain, J. P., &Hatzakis, A. (2013). Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology, 57(3), 908-916. 49. Paraskevis, D., Magiorkinis, G., Magiorkinis, E., Ho, S. Y., Belshaw, R., Allain, J. P., &Hatzakis, A. (2013). Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology, 57(3), 908-916. 50. Pastor, Rebecca, François Habersetzer, Samira Fafi-Kremer, Michel Doffoël, Thomas F. Baumert, Jean-Pierre Gut, Françoise Stoll-Keller, and Evelyne Schvoerer. "Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients." World Journal of Gastroenterology: WJG 15, no. 6 (2009): 753. 51. Pathoumthong, K., Khampanisong, P., Quet, F., Latthaphasavang, V., Souvong, V., & Buisson, Y. (2014). Vaccination status, knowledge and awareness towards hepatitis B among students of health professions in Vientiane, Lao PDR. Vaccine, 32(39), 4993-4999. 52. Patwardhan, V. R., Sengupta, N., Bonder, A., Lau, D., &Afdhal, N. H. (2014). Treatment cessation in noncirrhotic, e‐antigen negative chronic hepatitis B is safe and effective following prolonged anti‐viral suppression with nucleosides/nucleotides. Alimentary pharmacology & therapeutics, 40(7), 804-810. 53. Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of hepatology, 45(4), 529-538. 54. Rajoriya, N., Combet, C., Zoulim, F., & Janssen, H. L. (2017). How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualisedapproach?. Journal of hepatology, 67(6), 1281-1297. 55. Revill, P. A., Tu, T., Netter, H. J., Yuen, L. K., Locarnini, S. A., & Littlejohn, M. (2020). The evolution and clinical impact of hepatitis B virus genome diversity. Nature Reviews Gastroenterology & Hepatology, 17(10), 618-634. 56. Revill, Peter A., Francis V. Chisari, Joan M. Block, Maura Dandri, Adam J. Gehring, Haitao Guo, Jianming Hu et al. "A global scientific strategy to cure hepatitis B." The Lancet Gastroenterology & Hepatology 4, no. 7 (2019): 545-558. 57. Rivero-Juárez, A., Camacho, A., Merchante, N., Pérez-Camacho, I., Macias, J., Ortiz-Garcia, C., ... & Rivero, A. (2013). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One, 8(7), e68953. 58. Rivero-Juárez, A., Camacho, A., Merchante, N., Pérez-Camacho, I., Macias, J., Ortiz-Garcia, C., ... & Rivero, A. (2013). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One, 8(7), e68953. 59. Sakamoto, T., Tanaka, Y., Watanabe, T., Iijima, S., Kani, S., Sugiyama, M., ... &Mizokami, M. (2013). Mechanism of the dependence of hepatitis B virus genotype G on co‐infection with other genotypes for viral replication. Journal of viral hepatitis, 20(4), e27-e36. 60. Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Kao, J. H. (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international, 10(1), 1-98. 61. Schillie, S., Harris, A., Link-Gelles, R., Romero, J., Ward, J., & Nelson, N. (2018). Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. Morbidity and Mortality Weekly Report, 67(15), 455. 62. Schillie, S., Harris, A., Link-Gelles, R., Romero, J., Ward, J., & Nelson, N. (2018). Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. Morbidity and Mortality Weekly Report, 67(15), 455. 63. Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015). Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet, 386(10003), 1546-1555. 64. Seeger, C., & Mason, W. S. (2000). Hepatitis B virus biology. Microbiology and molecular biology reviews, 64(1), 51-68. 65. Seeger, C., & Mason, W. S. (2000). Hepatitis B virus biology. Microbiology and molecular biology reviews, 64(1), 51-68. 66. Seeger, C., & Mason, W. S. (2013). Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus. Gut, 62(8), 1093-1095. 67. Shin, A., Cho, E. R., Kim, J., Sung, J., Park, K. W., Lim, M. K., & Shin, H. R. (2009). Factors associated with awareness of infection status among chronic hepatitis B and C carriers in Korea. Cancer Epidemiology and Prevention Biomarkers, 18(6), 1894-1898. 68. Shinkai, Noboru, Kentaro Matsuura, FuminakaSugauchi, Tsunamasa Watanabe, Shuko Murakami, Etsuko Iio, Shintaro Ogawa, ShunsukeNojiri, Takashi Joh, and Yasuhito Tanaka. "Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance." Journal of clinical microbiology 51, no. 11 (2013): 3484-3491. 69. Solmone, M., Vincenti, D., Prosperi, M. C. F., Bruselles, A., Ippolito, G., &Capobianchi, M. R. (2009). Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis BS antigen. Journal of virology, 83(4), 1718-1726. 70. Song, L. W., Liu, P. G., Liu, C. J., Zhang, T. Y., Cheng, X. D., Wu, H. L., ... & Xia, N. S. (2015). Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clinical Microbiology and Infection, 21(2), 197-203. 71. Tatematsu, K., Tanaka, Y., Kurbanov, F., Sugauchi, F., Mano, S., Maeshiro, T., ... &Mizokami, M. (2009). A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. Journal of virology, 83(20), 10538-10547. 72. Tatematsu, K., Tanaka, Y., Kurbanov, F., Sugauchi, F., Mano, S., Maeshiro, T., ... &Mizokami, M. (2009). A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. Journal of virology, 83(20), 10538-10547. 73. Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, Main J, Nelson M, Rodger A, Taylor C, Youssef E. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS (London, England). 2017 Nov 28;31(18):2525. 74. Tozun, N., O. Ozdogan, Y. Cakaloglu, R. Idilman, Z. Karasu, U. L. U. S. Akarca, S. Kaymakoglu, and O. Ergonul. "Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study." Clinical Microbiology and Infection 21, no. 11 (2015): 1020-1026. WHO, World Hepatitis Day 2018, World Health Organization, 2018, https://www.who.int/campaigns/world-hepatitisday/2018. 75. Yeo, Yee Hui, Hsiu J. Ho, Hwai-I. Yang, Tai-Chung Tseng, Tetsuya Hosaka, Huy N. Trinh, Min-Sun Kwak et al. "Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis." Gastroenterology 156, no. 3 (2019): 635-646. 76. Yu, H., Yuan, Q., Ge, S. X., Wang, H. Y., Zhang, Y. L., Chen, Q. R., ... & Xia, N. S. (2010). Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype “I”. PloS one, 5(2), e9297. 77. Yuan, J. M., Ambinder, A., Fan, Y., Gao, Y. T., Mimi, C. Y., &Groopman, J. D. (2009). Prospective evaluation of hepatitis B 1762T/1764A mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiology and Prevention Biomarkers, 18(2), 590-594. 78. Zhang, X., Zhang, H., & Ye, L. (2006). Effects of hepatitis B virus X protein on the development of liver cancer. Journal of Laboratory and Clinical Medicine, 147(2), 58-66. 79. Zuckerman, J. N., & Zuckerman, A. J. (2003). Mutations of the surface protein of hepatitis B virus. Antiviral research, 60(2), 75-78. Y.-F. Liaw and C.-M. Chu, “Hepatitis B virus infection,” TheLancet, vol. 373, no. 9663, pp. 582–592, 2009

Refbacks

  • There are currently no refbacks.